| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 03/21/2013 | WO2013039859A1 Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
| 03/21/2013 | WO2013039792A1 Immunogens based on an hiv-1 gp120 v1v2 epitope |
| 03/21/2013 | WO2013039295A1 Novel alpha 1-antitrypsin variant, preparation method thereof, and use thereof |
| 03/21/2013 | WO2013039190A1 Peptide-containing polymer, and method for peptide immobilization on fiber |
| 03/21/2013 | WO2013039166A1 Method for measuring anti-wt1 antibody |
| 03/21/2013 | WO2013038696A1 Molecular marker for early indentification of pleural mesothelioma patients, and expression analysis method for same |
| 03/21/2013 | WO2013038666A1 Light-induced seizure model in rat brains |
| 03/21/2013 | WO2013038420A1 A novel method of isolation of tlr4 from cell lysates of monocular cells |
| 03/21/2013 | WO2013038385A2 Escherichia coli vaccine combination |
| 03/21/2013 | WO2013038376A1 Increase in meiotic recombination in plants by inhibiting the fancm protein |
| 03/21/2013 | WO2013038303A1 Plants having enhanced yield-related traits and methods for making the same |
| 03/21/2013 | WO2013038066A1 Modified oncolytic vaccinia virus |
| 03/21/2013 | WO2013037961A1 Anti-her2 vaccine based upon aav derived multimeric structures |
| 03/21/2013 | WO2013037841A2 Chimeric non-integrating lentiviral genomes as innovative vaccines against hiv-1 |
| 03/21/2013 | WO2013037824A1 Endoglycosidase from streptococcus pyogenes and methods using it |
| 03/21/2013 | WO2013037690A1 Glp-1 derivatives |
| 03/21/2013 | WO2013037521A1 Modified hgf-1k1 polypeptide |
| 03/21/2013 | WO2013037520A1 Modified hgf-1k1 polypeptide |
| 03/21/2013 | WO2013037267A1 Variant of liraglutide and conjugate thereof |
| 03/21/2013 | WO2013037266A1 Method for solid phase synthesis of liraglutide |
| 03/21/2013 | WO2013016148A3 Natriuretic peptide compositions and methods of preparation |
| 03/21/2013 | WO2013010119A3 Water-based prolamin compositions, methods of making water-based prolamin compositions, and applications thereof |
| 03/21/2013 | WO2013009935A3 Late blight resistance genes |
| 03/21/2013 | WO2012163817A3 Immunogenic composition |
| 03/21/2013 | WO2012140677A8 ISOLATION, CLONING, SEQUENCING AND FUNCTIONAL ANALYSIS OF β-CASEIN PROMOTER ALONG WITH THE REGIONS OF EXON1, INTRON1 AND EXON2 USING MAMMARY GLAND DERIVED CELL LINE OF BUFFALO (BUBULUS BUBALIS) |
| 03/21/2013 | US20130074222 Precise breeding |
| 03/21/2013 | US20130074217 Transgenic soybean plants exhibiting improved innate immunity |
| 03/21/2013 | US20130074214 Nitrogen Responsive Early Nodulin Gene |
| 03/21/2013 | US20130074199 Compositions and Methods for Brown Fat Induction and Activity Using FNDC5 |
| 03/21/2013 | US20130072702 Polynucleotide encoding nf-yb derived from jatropha and use thereof |
| 03/21/2013 | US20130072671 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 03/21/2013 | US20130072668 Method for producing hydroxylated adamantane using cytochrome p450 |
| 03/21/2013 | US20130072667 Use of rgm and its modulators |
| 03/21/2013 | US20130072658 Process for solubilizing glucagon-like peptide 1 compounds |
| 03/21/2013 | US20130072657 CELL GROWTH INHIBITOR DERIVED FROM p16INK4a AND METHOD OF SYNTHESIZING THE SAME |
| 03/21/2013 | US20130072446 Anti-inflammatory pharmaceutical products |
| 03/21/2013 | US20130072441 Protease Inhibitors and Preventives or Remedies for Disease |
| 03/21/2013 | US20130072439 Peptidomimetic macrocycles |
| 03/21/2013 | US20130072435 Tribonectins |
| 03/21/2013 | US20130072434 Inactivation resistant factor viii |
| 03/21/2013 | US20130072433 Inhibitors of beta integrin-g protein alpha subunit binding interactions |
| 03/21/2013 | US20130072425 Saposin-a derived peptides and uses thereof |
| 03/21/2013 | US20130072424 Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeutics |
| 03/21/2013 | US20130072420 Biosynthetic proline/alanine random coil polypeptides and their uses |
| 03/21/2013 | US20130072403 Sperm-specific cation channel, catsper3, and uses therefor |
| 03/21/2013 | US20130071878 Two helix binders |
| 03/21/2013 | US20130071864 Colorectal cancer marker vitronectin and method for analyzing vitronectin concentration in blood sample |
| 03/21/2013 | US20130071862 Fusion proteins and their use in the diagnosis and treatment of leishmaniasis |
| 03/21/2013 | US20130071645 Method for separating atelocollagen, method for preparing modified atelocollagen, atelocollagen prepared by using the same and collagen-based matrix |
| 03/21/2013 | US20130071434 Campylobacter Polypeptides and Methods of Use |
| 03/21/2013 | US20130071431 Method for Preserving Polypeptides Using A Sugar and Polyethyleneimine |
| 03/21/2013 | US20130071428 Peptides, conjugates and method for increasing immunogenicity of a vaccine |
| 03/21/2013 | US20130071424 Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein |
| 03/21/2013 | US20130071423 Combination vaccine for streptococcus |
| 03/21/2013 | US20130071419 Universal dengue virus sequences and methods of use |
| 03/21/2013 | US20130071418 Physicochemical (PCP) Based Consensus Sequences and Uses Thereof |
| 03/21/2013 | US20130071417 N-domain of carcinoembryonic antigen and compositions, methods and uses thereof |
| 03/21/2013 | US20130071416 Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae |
| 03/21/2013 | US20130071401 Methods of treating diabetes and compositions capable of same |
| 03/21/2013 | US20130071399 Immunogen and Antivenom Against Violin Spider Venom |
| 03/21/2013 | US20130071383 Selective modification of proteins |
| 03/21/2013 | US20130071381 Humanized anti-ccr2 antibodies and methods of use therefor |
| 03/21/2013 | US20130071366 Insulin-like growth factor ii (igf-ii) binding factors |
| 03/21/2013 | US20130071331 Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof |
| 03/21/2013 | US20130071320 Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| 03/21/2013 | DE10028725B4 Primärstruktur des HNA-2a (ehemals NB1)-Antigens Primary structure of the HNA-2a (formerly NB1) antigen |
| 03/21/2013 | CA2848976A1 Increase in meiotic recombination in plants by inhibiting the fancm protein |
| 03/21/2013 | CA2848919A1 Novel alpha 1-antitrypsin variant, preparation method thereof and use thereof |
| 03/21/2013 | CA2848841A1 Wnt compositions and therapeutic uses of such compositions |
| 03/21/2013 | CA2848765A1 Immunotherapy and diagnosis of mucormycosis using coth |
| 03/21/2013 | CA2848484A1 Chimeric non-integrating lentiviral genomes as vaccines against hiv-1 |
| 03/21/2013 | CA2848410A1 Rna engineered t cells for the treatment of cancer |
| 03/21/2013 | CA2848403A1 Hyr1-derived compositions and methods of treatment using same |
| 03/21/2013 | CA2848368A1 Compositions and methods for brown fat induction and activity using fndc5 |
| 03/21/2013 | CA2848351A1 Composition and dressing for wound treatment |
| 03/21/2013 | CA2848311A1 Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
| 03/21/2013 | CA2848230A1 Endoglycosidase from streptococcus pyogenes and methods using it |
| 03/21/2013 | CA2848209A1 T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| 03/21/2013 | CA2848204A1 Glucagon-like peptide-2 compositions and methods of making and using same |
| 03/21/2013 | CA2847079A1 Plants having enhanced yield-related traits and methods for making the same |
| 03/21/2013 | CA2846608A1 Pseudomonas exotoxin a with less immunogenic b cell epitopes |
| 03/21/2013 | CA2846479A1 Method for measuring anti-wt1 antibody |
| 03/21/2013 | CA2845599A1 Soybean bbi3 promoter and its use in embryo-specific expression of transgenic genes in plants |
| 03/20/2013 | EP2570484A1 Influenza virus-like particles (VLPS) comprising hemagglutinin |
| 03/20/2013 | EP2570431A2 Compositions and methods of using proislet peptides and analogs thereof |
| 03/20/2013 | EP2570430A2 Peptide vaccines with Seq ID No: 78, 41, 44, 46 or 48 for cancers expressing tumor-associated antigens |
| 03/20/2013 | EP2570429A2 Peptide vaccines with Seq ID No: 48, 41, 44, 46 or 78 for cancers expressing tumor-associated antigens |
| 03/20/2013 | EP2570428A2 Peptide vaccines with Seq ID No: 379 or 376 for cancers expressing tumor-associated antigens |
| 03/20/2013 | EP2570427A1 Vaccine comprising a Ribosomal Protein Extract (RPE) and optionally a Th1-promoting adjuvant |
| 03/20/2013 | EP2570426A1 Plants having enhanced yield-related traits and a method for making the same |
| 03/20/2013 | EP2570425A2 Deletions in domain II of Pseudomonas exotoxin A that reduce non-specific toxicity |
| 03/20/2013 | EP2570424A1 OB-Fold used as scaffold for engineering new specific binders |
| 03/20/2013 | EP2570423A1 Hepatitis C virus nucleic acid vaccine |
| 03/20/2013 | EP2570422A2 Promiscuous HER-2/NEU CD4 T cell epitopes |
| 03/20/2013 | EP2569633A2 Compositions and methods of identifying tumor specific neoantigens |
| 03/20/2013 | EP2569433A1 Modulation of scleraxis using a dominant negative scleraxis mutant with a basic dna-binding domain deletion |
| 03/20/2013 | EP2569424A1 Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof |
| 03/20/2013 | EP2569420A2 Method and composition for inducing human pluripotent stem cells |
| 03/20/2013 | EP2569419A2 Differentiation of human embryonic stem cells |
| 03/20/2013 | EP2569332A1 Improved complement receptor 2 (cr2) targeting groups |